PolyNovo sales growth slows as lockdowns hit surgery rates

Yolanda RedrupRich List co-editor

Feb 23, 2021 – 11.59am

Email LinkedIn Twitter Facebook

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Key Points

Revenue ($m) 12.y6, up 24pc from year-earlier 10.2
Pretax loss ($m) 3.5 v 2.4
Net loss ($m) 3.5 v 2.4
No interim dividend

The development of new products in the pipeline for skin regeneration biotechnology company PolyNovo has been pushed back at least six months thanks to COVID-19, according to CEO Paul Brennan.

The delay to new products comes as the business also experienced a slowdown in second-quarter sales, which constrained its revenue growth to 24 per cent for the first half, as it hit $12.6 million.